Rocky Mountain High Brands, Inc. (RMHB) Signs LOI With Comanche Family to Produce Authentic Rocky Mountain Spring Water

Rocky Mountain High Brands, Inc. (RMHB) Signs LOI With Comanche Family to Produce Authentic Rocky Mountain Spring Water

DALLAS, Nov. 24, 2015 (GLOBE NEWSWIRE) — Rocky Mountain High Brands, Inc. (RMHB) announced today that the Company has signed a LOI (Letter of Intent) to work with a Native Comanche Indian Family of Oklahoma to produce ‘Original Rocky Mountain Spring Water’ from the original Ancestral Rockies Springs located in the now present Wichita Mountains.

The Wichita Mountains are located in the southwestern portion of Oklahoma. The mountains are a northwest-southeast trending series of rocky promontories, many capped by 540 million year-old granite. The Wichita Mountains are part of the range that was called the Ancestral Rockies and were formed several million years before the present day Colorado Rocky Mountains. The natural spring water will be derived from the original springs that feed the Chandler Creek. This is where the last Comanche Tribe eagle doctor, Mary (Sanapia) Poafpybitty lived and treated her patients by requiring them to drink and bathe in the Spring Water due to its healing powers.

Rocky Mountain High Brands plans to form a joint venture with the Comanche family to produce and market a line of Hemp-infused flavored waters derived from the ‘Healing Spring Waters’ located in the Slick Hills at the base of the Wichita Mountains.

Also contained in the LOI agreement that is in place is to grow and produce hemp on a 157 acre parcel of the Comanche family land. There is an option to increase the size of the parcel as the need arises.


Special Foods that have an incredible array of health benefits well beyond just their nutrient value are considered ‘Super Foods’. Hemp is an incredible multi-purpose plant that can be used for anything from paper, rope, and cloth. It is also one of the most nutritionally well-balanced foods on the planet.

“The formation of a joint venture with the Comanche family to produce a product line of ‘Original Rocky Mountain High Hemp Spring Waters’ is a naturally perfectly fit for health conscience people. Native American Indian ‘Healing Spring Waters’ infused with ‘Super Food’ hemp extract will potentially create a product that will dominate the exponentially growing bottled water market. According to a report published by Transparency Market Research, the bottled water industry was valued at $157 billion in 2013 and is expected to reach $279 billion by 2020. Rocky Mountain High plans to introduce the new health water product in 2016,” said Jerry Grisaffi, Founder of Rocky Mountain High Brands.

For Rocky Mountain High Distribution Contact:
Todd Kornely: (972) 804-9620
For Rocky Mountain High CBD Opportunities:
Jason Robillard: (972) 804-9620
 About Rocky Mountain High Brands, Inc.:
Our Mission is to be the premier Hemp-Infused Beverage Company in the World. RMHB formerly traded as THCZ.
Visit our Corporate Website at:
Investors Hangout is the only authorized Investors blog page for Rocky Mountain High Brands, Inc.

AEMD: Meets 5 Objective, New ADAPT Program To Broaden Applications

AEMD: Meets 5 Objective, New ADAPT Program To Broaden Applications

Zacks Small Cap Research

By Brian Marckx, CFA


Fiscal Q2 2016 Financials, Operational Update
Aethlon Medical (AEMD) reported financial results for their fiscal second quarter 2016 and provided an operational update.  Results continue to come in very much inline with our estimates including revenue (a hair lower), OpEx (on the nose) and net income/EPS (inline).  On the call management summarized their operational progress, which included meeting all of their five objectives that they outlined on their fiscal Q1 conference call held in August.  
In addition to these objectives AEMD has made progress on other fronts, including realizing a breakthrough that should dramatically reduce the production cost of the key affinity agent used in Hemopurifier.  And the company now has other new irons in the fire, including what they are calling Aethlon ADAPT which will focus on broadening the applications for their affinity biofiltration technology in other diseases through partnerships.    
Q2 revenue was $188k, consisting of $186k of DARPA grants and $2k from the Battelle subcontract, compared to our $201k estimate which consisted of $200k in DARPA revenue and $1k from Battelle.  The DARPA revenue relates to the 26th milestone.  In late September AEMD announced that they were awarded year 5 of the DARPA contract which is the final year and will pay up to $581k if all the requisite milestones are met.  On the call management noted that they are in process of preparing to bill for the next DARPA milestone of $297k.     
Q2 OpEx was $1.3M, inline with our $1.3M estimate.  We continue to expect operating expenses to trend higher as a result of increased clinical trial activities related to the U.S. HCV and cancer studies as well as some incremental hiring to support other areas of the business.  Net loss and EPS were $1.2M and ($0.16), compared to our $1.3M and ($0.17) estimates.  AEMD exited the quarter with $4.2M in cash, down from $5.7M at the end of Q1.  Management expects the cash balance to be sufficient to fund for fiscal 2016 (ending 3/31/2016).         
Operational Update:  Meets All 5 Objectives, Aethlon ADAPT, Additional Progress… 
On the fiscal first quarter conference call in August management laid out five specific objectives that they planned to accomplish over the following months.  They successfully did so and went through each one on the Q2 call, which we have provided an update to below.  But in addition to meeting these goals the company also made parallel progress in not only further shoring up their operational capabilities in preparation for increased activities related to both the HCV and cancer applications but also made strides in broadening the scope of potential applications where their technology might be applied.  
A recap and update to the five objectives that the company laid out on the Q1 call in August…. 
– Collect an additional ~$200k under the DAPRA contract which relates to year 4.  Hope to be granted year 5 of the contract (which was subsequently awarded).  Accomplished with $186k collected in Q2 and DARPA year 5 awarded in September.  
– Submission of manuscript of the DETECT (Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests) study.  As a reminder, since late last calendar year Aethlon’s majority-owned subsidiary Exosome Sciences (ESI) has collaborated with Boston University’s CTE Center for the development of a blood-based diagnostic that would be able to identify CTE in living individuals.  ESI has used what they learned in how to isolate certain brain-specific biomarkers to evaluate blood samples collected by participants (former NFL players and a control group) enrolled in BU’s DETECT study.  The study is the first on CTE funded by the NIH. Aethlon submitted the manuscript subsequent to the Q1 call.  Management noted on the Q2 call that they think it could be published within the next ~60 days.  As an aside, the night before AEMD’s earnings call there was a timely 60 Minutes story about BU’s CTE study and the blood-based diagnostic that AEMD’s Exosome Sciences is helping lead the development of.  
– Accelerate cancer study with University of California, Irvine.  As a reminder, in mid-April AMED announced that they entered an agreement with UC, Irvine to conduct an investigator-initiated study with various cancer types including breast, colorectal lung, head and neck and others.  Targeted enrollment is five patients in each of nine cancer types (45 patients total) including breast adenocarcinoma, colorectal, gastric and gastroesophageal, pancreatic, cholangiocarcinoma, lung, head and neck, melanoma and ovarian adenocarcinoma.  The proposed study protocol, Plasma Exosome Concentration in Cancer Patients Undergoing Treatment”, will monitor changes in circulating exosome levels and their association with cancer treatment and response to treatment.  In May AEMD announced that UC, Irvine Medical Center approved an IRB to commence the study.  AEMD noted on the Q2 call that this study has commenced and has now enrolled three patients so far.         
– Advance additional collaborations for Hemopurifier in cancer and infectious diseases.  As a reminder, Hemopurifier has shown potential utility in HCV, HIV, Ebola, other pandemic diseases, bioterror applications, cancer and other areas.  AEMD is clearly focused on deepening and broadening the potential applications that their device may have utility for.  In June the company announced an agreement with the India’s National Institute of Virology to commence testing of Hemopurifier for treatment of Chikungunya.  Management also noted on the Q2 call that they have initiated a research project with the National Center for Biodefense and Infectious Diseases to investigate the use of Hemopurifier in Venezuelan equine encephalitis.  AEMD has had a relationship with the National Center for Biodefense and Infectious Diseases for over ten years and this latest announcement appears to be further progress towards working with the center for applications of AEMD’s technology in addressing biological threats.   
– Initiate the U.S. HCV feasibility study and transition Dr. Stephen Fadem from principal investigator of the study to a medical advisory role within the company.  Subsequent to the Q1 call that transition was made and Dr. Ronal Ralph was brought on as the new principal investigator.  AEMD expects to hire two sub-principal investigators to help further accelerate the trial schedule.  And while progression of the study has been drawn out longer than initially anticipated, AEMD noted on the Q2 call that they expect to have the new study team trained after Thanksgiving and begin new patient enrollment in January.   
Aethlon ADAPT
In early November the company announced a new initiative at the IN3 Medical Device 360 Summit Conference in San Francisco called Aethlon ADAPT.  ADAPT, is an acronym for the company’s technology and stands for Adaptive Dialysis-like Affinity Platform Technology.  The Aethlon ADAPT initiative is focused on partnering with organizations in development of other affinity bio-filtration devices to address other diseases, which is a program that will run parallel to AEMD’s individual efforts.  We view this as a way to de-risk (at least from a financial standpoint) and, potentially accelerate, development of their technology in a broader spectrum of diseases and applications.           
AEMD Picks Up Operational Momentum in FY2016
Fiscal 2015 saw several highlights with progress of both the Hemopurifier program as well as with ESI.  In addition, management made tremendous progress with shoring up the balance sheet, eliminating almost all debt.  AEMD built on their operational momentum over the last several months including a Nasdaq uplisting, $6 million equity raise and further progress with expanding the potential indications for Hemopurifier.  AEMD began trading on Nasdaq in mid-July which followed a 1 for 50 reverse split.  This should provide for greater investor visibility and, with the stock trading over $5, provide greater access to institutional investors.  
The $6 million ($5.6M net) raise was done at $6.30/share and came with 75% warrant coverage ($6.30 strike, five years).  As we mentioned in our June 24 investor note, this raise continues to confirm the company’s ability to bring on additional capital at reasonable terms and without compromising the balance sheet – which had been an issue in the past.  It also should provide a substantial runway for the company to further its development programs.  The shares continue to trade higher than the offering price.   
AEMD has also been very aggressive in looking for potential new indications for Hemopurifier.  As a reminder, HCV had been the only real main focus for the company just a couple of years ago.  Since then they have ramped up activities in several other areas, most notably cancer and Ebola, and at the same time made significant progress on the HCV indication.  Clinical studies in all of these areas have already been planned, the U.S. HCV study is finally starting to gain traction and the cancer study now has three patients enrolled.  Studies in other indications could start in the near-term.  And the new Aethlon ADAPT initiative, which is focused on partnering for development of other affinity bio-filtration devices to address other diseases could accelerate broadening the applications for the technology while at the same time de-risking cost of development through partnerships. 
In early June management announced an agreement with the National Institute of Virology to commence testing of Hemopurifier for treatment of Chikungunya.  Chikungunya is a virus passed from mosquitoes with recent outbreaks in the Americas, Europe and Asia.  Records indicate that people in at least 44 countries have had exposure to Chikungunya.  Symptoms include fever, sometimes severe, and joint pain which can last from weeks to years.  During one outbreak in 2006 over 50% of those infected reported long-term joint pain.  As there is no currently known treatment for the virus, Hemopurifier, if deemed effective and safe, could be the eventual standard of care.  We expect to hear more about this collaboration and planned studies in the near future.  
Operational Update: 
U.S. HCV Study: Commencement of the U.S. HCV study, while delayed from initial expectations, finally kicked off with the first patient completing treatment in late February.  Subsequent to that AEMD announced that the second and third patient.  However, the study all but stalled until recently as a new principal investigator was sought.  A new principal investigator has now been brought on and two sub-principal investigators are expected to be hired in the near-term to help to accelerate timelines.  AEMD noted on the Q2 call that they expect to have the new study team trained after Thanksgiving and begin new patient enrollment in January.  
As a reminder, this is a safety study being conducted at DaVita Medical Center Dialysis in Houston with target enrollment of 10 HCV-infected patients who are already undergoing dialysis.  Patients will receive Hemopurifier treatment three times per week for two weeks.  This is primarily a safety study but secondary outcomes including quantity of captured viral copies and change in viral load will also be measured.  Per the study protocol on, estimated completion date is December 2015 – although due to delays in getting the study moving, that timeline will not be met and we expect the trial to complete sometime in calendar 2016.  Results which were initially expected to be used solely for support of FDA approval to conduct larger pivotal studies in HCV as well as potentially other diseases such as HIV and cancer, may now also include pursuit of clinical studies for other viruses, including Ebola and other category A threats. 
Ebola:  As we have discussed in recent updates, AEMD appears to be getting closer to realizing Ebola as a viable opportunity for Hemopurifier.  As a reminder, in mid-October 2014 AEMD announced that Hemopurifier was being used on an Ebola patient for the first time.  Introduction of Hemopurifier was made possible by a special approval from the German Federal Institute for Drugs and Medical Devices.  The patient, a Ugandan doctor who contracted the virus in Sierra Leone, was treated at Frankfurt Hospital in Germany.  About three weeks later the company announced that the hospital reported that the patient had undetectable levels of Ebola.  He was subsequently released from the hospital.   
The Chief of Nephrology at the hospital where the patient was treated presented the treatment findings at the American Society of Nephrology (ASN) Annual Meeting on November 14th 2014 during a special session on Ebola.  Hemopurifier captured 242 million copies of Ebola.  Hemopurifier was introduced 13 days after the patient was diagnosed with Ebola.  Prior to Hemopurifier administration, the patient had multiple organ failure, was unconscious and had a viral load of 400k virus copies/ml.  Following a 6.5 hour treatment with Hemopurifier viral load was 1k virus copies/ml. 
The experience was documented in a manuscript published in the journal Blood Purification in February.  The article, titled Extracorporeal Virus Elimination for the Treatment of Severe Ebola Virus Disease – First Experience with Lectin Affinity Plasmepheris, was written by the physician that administered the therapy and his colleagues.  
Among the highlights, the article notes; 
– “Notwithstanding scientific efforts and anecdotal reports of successful interventions, no EBOV [Ebola virus]-specific therapy has proved to be efficient to this point.” “An entirely new approach is the extracorporeal elimination of viruses and viral GP [glycoproteins] by lectin affinity plasmapheresis ((LAP).” 
– reported “for the first time the successful and safe use of lectin affinity plasmapheresis in a patient with severe Ebola virus disease (EVD)” 
– there were no adverse events and Hemopurifier treatment was well tolerated 
– viral load just prior to Hemopurifier therapy was 3.78 x 105  and fell to 6.08 x 10the following day. This represents a 62 times reduction in viral load 
– 253 million copies of Ebola virus were captured by Hemopurifier (slightly more than initially calculated) 
– Viral load was undetectable and the patient fully recovered six days after Hemopurfier treatment 
– the authors note that by reducing the number of circulating viruses via plasmapheresis, the body’s natural immune response is freed up to attack and eliminate the remaining virus 
– “The data contained in this case study represents a ‘proof of concept’ for extracorporeal virus removal in EVD.” “We consider that LAP is a new option to expand best supportive care toward a virus-targeted therapy for EVD.” 
– the authors acknowledge that while this case provided definitive evidence that Hemopurifier is able to capture significant Ebola virus copies, that it is not possible to conclude that Hemopurifier treatment alone was the reason for recovery of the patient.  However, they also note that this case “provides optimism that LAP is a promising new tool for the treatment of severe Ebola virus infection, and warrants further evaluation as well as technical development.”  
U.S. HUD Ebola Submission: shortly following the positive outcomes of the first Ebola patient treated with Hemopurifier AEMD filed a Humanitarian Use Device (HUD) submission with the FDA.  The April 9th submission seeks eventual designation by FDA for use of Hemopurifier in the treatment of individuals with Ebola in the U.S.  The next step, assuming FDA designates Hemopurifier HUD status, will be for AEMD to submit an application seeking Humanitarian Device Exemption.  
U.S. Ebola Study: While HDE approval does not typically require the applicant to demonstrate effectiveness through clinical trials, AEMD may pursue a multi-site (up to) 20-patient investigational Ebola study that FDA approved the protocol for in January.  Hemopurifier therapy will be administered daily for six to eight hours until Ebola viral load falls below 1k copies/ml.  Timetables for commencement of this study have not been offered.  And enrollment will likely be a challenge given the dearth of Ebola-infected individuals, particularly those that are treated in the U.S.  Despite this, we view the protocol approval, positive outcomes of the first Ebola patient treated with Hemopurifier and the recent HDE submission as very positive steps.    
Ebola Canadian Study: More recently, in May 2015, Health Canada approved an Ebola study protocol titled, The Treatment of Ebola Virus Disease in Humans with the Aethlon Hemopurifier Lectin Affinity Plasmapheresis Device. The protocol would include up to three patients.  Similar to the U.S. study protocol, there are also no timelines for commencement of a study in Canada and recruitment will likely also be challenging, albeit this Canadian study would only enroll up to three patients.
Progress towards CTE, Cancer… 
CTE: As a reminder, in March 2014 AEMD announced that ESI has been investigating certain brain-specific biomarkers and whether they can be identified in circulating exosomes.  ESI has isolated the brain-specific biomarkers tau, beta-amyloid, glycoprotein A2B5 and S100B in the circulatory system – previously only identified in cerebrospinal fluid.  These biomarkers have been shown to be associated with Alzheimer’s Disease (beta-amyloid), Chronic Traumatic Encephalopathy (tau) and traumatic brain injury.  There is currently no cure for these disorders and identifying their presence is often not possibly until either well into their progression or, in the case of Chronic Traumatic Encephalopathy (CTE), until an autopsy is done.  CTE has received significant mainstream media attention of late as it been associated with head injuries of NFL players and been implicated as a cause for severe depression and some resultant suicides. 
Then in late September 2014 AEMD announced that they and ESI entered into a collaboration with Boston University’s CTE Center in development of a blood-based diagnostic that would be able to identify CTE in living individuals.  Development of an accurate test for CTE in living individuals would be a breakthrough for diagnosing the condition and could lead to improvement in care.  Noteworthy is that in November 60 Minutes did a story about BU’s CTE study and the blood-based diagnostic that AEMD’s Exosome Sciences is helping lead the development of.  
ESI is using what they learned in how to isolate certain brain-specific biomarkers to evaluate blood samples collected by participants (former NFL players and a control group) enrolled in BU’s DETECT (Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests) study.  The study is the first on CTE funded by the NIH.
In mid-April investigators presented initial findings of DETECT at the annual Traumatic Brain Injury Conference held in Washington, DC.  Results were from 78 former NFL players and 16 controls and showed that the NFL players had significantly higher levels of tausome (tau) in their blood than those of the controls.  Tau levels were also correlated to performance on memory tests, with higher tau levels corresponding to poorer test performance. Aethlon recently submitted a manuscript of the results for publication  – which management noted they believe could be published by the mid-January 2016 timeframe. 
Hemopurifier in Cancer:  As we have noted in recent updates, based on preliminary research, Hemopurifier may have utility in the treatment of cancer.  A potential application in cancer received arguably additional support in an article titled, “Extracellular Vesicles: Emerging Target for Cancer Therapy” published in the April 2014 issue of the journal, Trends in Molecular Medicine. The article, written by researchers at Harvard Medical School, Massachusetts General Hospital and University of Oxford explores evidence that extracellular vesicles (i.e. – exosomes) play a key role in cancer development and progression and suppression of immune response.  As such, extracellular vesicles (EVs) have increasingly become targets for anticancer therapy.  This coincides with AEMD’s cancer research and how Hemopurifier, via the removal of circulating cancer-secreted exosomes, could have utility in the treatment of cancer.  
The authors also believe that EVs may also increase the body’s resistance to cancer drugs and hinder their effectiveness.  They further note that, while early evidence suggests that inhibition of EV biogenesis may have beneficial effects in the treatment of cancer, that a challenge has been to find therapies that can specifically target cancer related EVs without affecting normal cell function.  The researchers specifically reference Hemopurifier as a potential therapy to overcome these challenges, noting that with the use of Hemopurifier “it might be possible to specifically capture tumour cell-derived EVs on an antibody-coated matrix during extracorporeal dialysis.  For example, in human epidermal growth factor receptor-2 (HER-2) overexpressing breast cancer, where HER-2-expressing EVs have been shown to interfere with therapy and are associated with tumour aggressiveness, anti-HER-2 antibodies could be used to remove HER-2-expressing EVs from circulation with the aim of improving therapeutic outcome. In principal, this approach could be tailored for other tumour types, as long as the tumour cell-derived EVs are enriched for tumour-specific proteins. However, whether the level and duration of EV depletion after ADAPT (i.e. – Hemopurifier) therapy would be sufficient to achieve a clinically relevant outcome remains to be determined.” 
The authors note that their current understanding of EVs role in cancer development and progression is still in the relatively early stages and is based on data from in vitro experiments.  Their acknowledgement of Hemopurifier as potentially having utility in the treatment of cancer is also largely based on the supposition that removal of circulating EVs may be beneficial in interrupting the development and spread of tumors – which is still just a theory at this point.  Nonetheless, we think this research does add meaningful credibility to Hemopurifier’s potential role in cancer suppression and adds additional support to AEMD’s research which indicates the same. 
As we had previously noted, we had anticipated that cancer-related studies might be on the horizon.  This recently became more of a reality when in mid-April AMED announced that they entered an agreement with the University of California, Irvine to conduct an investigator-initiated study with various cancer types including breast, colorectal lung, head and neck and others.  Targeted enrollment will be five patients in each of nine cancer types (45 patients total) including breast adenocarcinoma, colorectal, gastric and gastroesophageal, pancreatic, cholangiocarcinoma, lung, head and neck, melanoma and ovarian adenocarcinoma.  The proposed study protocol, Plasma Exosome Concentration in Cancer Patients Undergoing Treatment”, will monitor changes in circulating exosome levels and their association with cancer treatment and response to treatment.  In May AEMD announced that UC, Irvine Medical Center approved an IRB to commence the study.  Then in November AEMD noted that this study has commenced and has now enrolled three patients so far.               
Exosome Sciences and Cancer: ESI was formed to be not only a supplement to AEMD’s Hemopurifier business but also as a complement to it.  Much of ESI’s research has focused on diagnostics that could be developed to identify conditions where Hemopurifier treatment may be appropriate.  One of those areas, as discussed above is CTE (as well as other brain-specific applications), another is cancer.  
ESI recently made its first major foray into advancing its cancer research with the early April announcement of a research collaboration with Thomas Jefferson University (Philadelphia).  While few details were provided, the duo will work to develop a “liquid biopsy” to better diagnose and monitor cancers of the head and neck.  The research will focus on the role of exosomes and how they may act as a marker to help predict response to therapy, which is a similar endpoint in the recently proposed UC, Irvine investigator-initiated study.      
Maintaining Outperform Recommendation
The company continues to make substantive positive progress on several fronts including strengthening the balance sheet and ongoing ability to raise capital, diligence on cash burn and operating expenses, initiating the U.S. studies in HCV and cancer, scoring additional government grants and broadening into what we believe are more commercializable and attractive markets for Hemopurifier.  
We note our model still does not incorporate potential revenue contribution from indications outside of HCV, DARPA or Battelle – although with the recent substantive expansion into other indications such as Ebola, cancer and others (including via the Aethlon ADAPT program) as well as directly from ESI, our model is subject to updating based on successful further progress.  
Aethlon affected a 1 for 50 reverse stock in mid-April.  Current market discount rate, calculated by CAPM is approximately 9%.  Based on our DCF model and a 9% discount rate, AEMD is valued at approximately $18/share.  We are maintaining our Buy rating.  See below for access to our updated report on AEMD. 

NXT-ID Featured on The RedChip Money Report Airing on Bloomberg Network

NXT-ID Featured on The RedChip Money Report Airing on Bloomberg Network

PR Newswire

OXFORD, Connecticut, November 20, 2015 /PRNewswire/ —

NXT-ID, Inc. (NXTD) (“NXT-ID” or the “Company”), a biometric authentication company focused on the growing mobile commerce market and creator of the Wocket® smart wallet, announces its CEO, Gino Pereira, was recently interviewed on The RedChip Money Report television program. The interview will air on this weekend on Bloomberg Europe, Bloomberg Asia, Bloomberg Australia, and Bloomberg Latin America.

The interview segment can be viewed online here.

“The RedChip Money Report” delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The show is hosted by Dave Gentry, a leading authority on small-cap stocks and the author of Small Stocks, Big Money, published by Wiley Finance. Gentry has made multiple guest appearances on both CNBC and Fox Business News.

The interview with Pereira focuses on the Company’s Wocket® technology. Wocket is the smartest wallet you’ll ever own. Designed to protect your identity and replace your old wallet, simply swipe and save your cards into Wocket once and they are immediately secured with pin and biometric voice print technology.  Without ever needing a smartphone, you can choose a card from the touch screen and Wocket programs its single, smart card (Wocket Card) to match your selection. From there, you just swipe as you normally would virtually anywhere that credit cards are accepted today.
All your credit, debit, loyalty, gift, ID, membership, insurance, medical information, passwords, and other information can be protected on Wocket®.

Buy Wocket® at

See the full Wocket® FAQ at:

Product images are available for media at:

About NXT- ID Inc. – Mobile Security for a Mobile World: (NXTD)

NXT-ID, Inc.’s innovative MobileBio® solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio® suite of biometric solutions that secure consumers’ mobile platforms led by Wocket®; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. Wocket was recognized as one of the top technology products at CES 2015 by multiple media outlets including The Wocket works most anywhere credit cards are accepted and only works with your biometric stamp of approval or passcode.
NXT-ID’s wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification and has 22 licensed patents in the field of 3D facial recognition



Acquisition of EU promotions and gifting company to meet consumer demand for local, leisure-themed gift cards

PLEASANTON, California, Nov. 19, 2015 /PRNewswire/ —

Prepaid and payments company Blackhawk Network announced today that it has acquired DIDIX Gifting & Promotions. DIDIX, based in the Netherlands, issues and markets leisure-themed gifts and promotions using a prepaid card that can be redeemed to pay for services at multiple leisure outlets, including regional retailers, restaurants, cinemas and spas.

DIDIX is a market leader in developing gifting and promotional products and brands across the Netherlands, the United Kingdom, Germany and Belgium. It issues a number of top selling gifting products across leisure-brand categories with brands like Restaurant Choice in the UK, RestaurantCadeau, BioscoopCadeau, De Nederlandse Sauna Cadeaubon and Momento in the Netherlands, Restaurant Geschenk in Germany and CinemaCadeau in Belgium.

“We’re delighted to have acquired such an innovative, high-growth company with an excellent culture, management team and focus,” said Matthew Howe, managing director, Europe at Blackhawk Network. “This acquisition expands Blackhawk Network’s growing footprint in international markets and strengthens our position as an innovator in the gift card space.”

DIDIX products are sold to millions of consumers each year directly through retail, online and business-to-business (B2B) channels. Through the acquisition, Blackhawk Network intends to expand DIDIX’s reach by selling its products through Blackhawk’s extensive network of B2B, retail and digital channels.

“Strategic partnerships with retailers, cinema chains and restaurants are the backbone of our business,” said Jonathan Kenny, CEO, DIDIX. “We’re thrilled to become part of Blackhawk and benefit from its partnerships with popular and well-loved brands to complement our leisure-themed gifting and promotion experience.”

For more information, visit:

About Blackhawk Network

Blackhawk Network Holdings, Inc. (NASDAQ: HAWK) is a leading prepaid and payments global company, which supports the program management and distribution of gift cards, prepaid telecom products and financial service products in a number of different retail, digital and incentive channels. Blackhawk’s digital platform supports prepaid across a network of digital distribution partners including retailers, financial service providers, and mobile wallets. For more information, please visit and

About DIDIX Gifting & Promotions

DIDIX is a market leader in the issuing of leisure themed gift cards and promotions in the Netherlands, the United Kingdom and Belgium. DIDIX owns several well-known gifting brands such as RestaurantCadeau, BioscoopCadeau, De Nederlandse Sauna Cadeaubon, De Nationale Kadobon, Beauty&ParfumCadeau, CinemaCadeau and Restaurant Choice and experience activities boxes such as HEMA Lekker Weg and Momento.

“GIANT Night of Comedy Team” Presented by Rocky Mountain High Brands, Inc. (RMHB)

New York Giants and Jets Team Up for Rashad Jennings Foundation “GIANT Night of Comedy Team” Presented by Rocky Mountain High Brands, Inc. (RMHB)

DALLAS, Nov. 17, 2015 (GLOBE NEWSWIRE) — Rocky Mountain High Brands, Inc. (RMHB) announce today that they have teamed up to present the “GIANT Night of Comedy Team” Fundraiser Reception and Comedy Show at the infamous Gotham Comedy Club on Monday, November 30th.

The star studded show  will be held at the Gotham Comedy Club located in New York City and hailed by USA Today as “One of the Top 10 Places in the Country to See Stand-up”. This 15-year veteran club has been featured on NBC’s ‘Last Comic Standing,’ ‘The Celebrity Apprentice’ and is home to Comedy Central’s hit show ‘Live at Gotham’.

Comedy heavyweights such as Jerry Seinfeld, Dave Chappelle, Colin Quinn and Lewis Black, Adam Ferrara, Anthony Anderson, Dave Attell, Louis C.K., Dane Cook, Susie Essman, Jeff Garlin and too many more great comedians and comics to mention have all taken the stage at this fun upscale New York City Comedy Club.

To Purchase Tickets for the Fundraising Event:

Rashad Jennings Foundation

The GIANT Night of Comedy Team:

NY Giants’ Rashad JENNINGS, Eli MANNING QB NY Giants, Andre WILLIAMS RB NY Giants, Shane VEREEN RB NY Giants, Justin PUGH OL NY Giants, Prince AMAKUMARA CB NY Giants, Dominique ROGERS-CROMARTIE CB NY Giants, Quinton COUPLES LB NY Jets, Leger DOUZABLE DT NY Jets, Celebrity Friends and Teammates.

Continue reading ““GIANT Night of Comedy Team” Presented by Rocky Mountain High Brands, Inc. (RMHB)”

Kroger’s Purchase Of Roundy’s Is A Win!

Kroger announced it will purchase Roundy’s for $3.60/sh.
Though a large premium, I think the bid saves Roundy’s from impending bankruptcy.
The well-capitalized Kroger will provide a huge boost to stores in both of Roundy’s markets.
Both stocks are fairly valued, but this was an excellent acquisition for Kroger.

Early Wednesday morning, Kroger (NYSE:KR) announced that it purchased the dismally performing Roundy’s (NYSE:RNDY) for $3.60 per share in cash as well as the assumption of Roundy’s $641m in long-term debt and capital lease obligations, ultimately valuing the company at $800m. Though Roundy’s seemed down the path to bankruptcy, Kroger is ultimately a stronger competitor with much greater scale and financial strength that should help drive comp turnarounds at Wisconsin stores will bolstering the growth rate of Mariano’s in the Chicago area and beyond.

The clear winners in this situation are Roundy’s capital holders, Kroger, and those in the markets served by existing Roundy’s stores. Competitors in bot the Chicago market and Wisconsin market have the most to lose to their newly well-capitalized, enormous competitors.

Roundy’s capital holders-particularly equity-the big winners

Any time a deal is announced to have a 60%+ premium, one naturally assumes the equity holders made a big win. This likely is not the case with most of the Roundy’s shareholder base. After going public at over $9 a share in 2012, shares had fallen as low as $2. Even after the “64%” premium, Roundy’s will have lost over two thirds of its value since its IPO. While a weakening core business certainly did not help the cause, the real cause of Roundy’s downfall was its awful capital structure.
Private equity owner Willis Stein took it public with a cumbersome debt load and huge dividend meant to help goose the returns on its Roundy’s investment that just hadn’t worked out. In the interim, CEO Bob Mariano launched the Mariano’s banner to great fanfare in the Chicago area. As the long time CEO of Dominick’s, Mariano knew how to appeal to Chicagoland shoppers and knew how to pick out some great real estate. The store has done fantastically well-growing to 34 locations since 2011.

In order to grow the Mariano’s brand, Roundy’s shed non-core assets, including a chain of stores in Minnesota, and harvested cash flow from its Wisconsin business. The firm also took on junk-rated debt that paid 10.25% in annual interest charges. Though Mariano’s thrived, the Wisconsin business was hit by underinvestment and competition from the likes of Wal-Mart (NYSE:WMT), Target (NYSE:TGT), and Woodman’s. This year alone, same-store sales in Wisconsin have fallen 2.3% YTD while total Wisconsin sales are down 4.5%. FY14 same-store sales were down 4.2% in Wisconsin.
Even after adjusting for non-cash charges, the company has not made money in 2015, and, in my view, it had no clear path to making any money in the next few years. As a going concern, there’s a strong likelihood that the company would have run out of cash in 2-3 years and been forced into bankruptcy. The fact that equity holders received anything given the company’s precarious position is a miracle.

As for debt holders, the days of a 10%+ return on the debt are over; however, Kroger’s will refinance the debt at a lower rate and significantly lower risk profile. This prevents bondholders from spending years sorting out the capital structure in bankruptcy court.

Kroger’s enters two new markets & gains a new platform

In total, Kroger will pay about 0.2x sales for Roundy’s. Importantly, this acquisition gives Kroger a strong entry into two markets it previously eschewed: Wisconsin and Chicago.

Kroger plans to invest in the Wisconsin market to drive growth, and when you consider the $40m+ in overhead synergies and the additional leverage from Kroger’s house brands and superior purchasing scale, it is easy to see how the company can get the Wisconsin business back on track. Additionally, management noted that the Wisconsin market is similar to other markets it presently operates in, thus generating confidence about the ability to drive superior results.

As for Chicago, it sounds like Kroger will utilize industry veteran Bob Mariano to grow the Mariano’s banner. Kroger operates the no-frills Food 4 Less, so Mariano’s provides the company a chance to significantly rise up the value chain. Mariano’s has proven to be a formidable foe for Whole Foods (NASDAQ:WFM) in the Chicago market, and it is even partially responsible for Safeway’s closure of the Dominick’s banner.

Even more interesting, Kroger management hinted at the ability to leverage the Mariano’s banner in other markets. From anecdotal experience, it is hard not to appreciate Mariano’s mix of upscale fixtures, its in-store shopping experience (gelato, coffee, great prepared food), and compelling product mix that is augmented by real value prices. The banner will need some tweaks here and there, but ultimately, it is a leverageable platform that should be able to tackle Whole Foods and other upscale grocers.

Wal-Mart, Whole Foods, and Other Competitors Lose

The one limiting factor for both the Roundy’s Wisconsin stores and Mariano’s has always been capital. Stores in Wisconsin suffer from underinvestment and price wars from Wal-Mart, Target, and Woodman’s. In Illinois, Mariano’s has clicked with consumers, but the company can’t expand enough, and, frankly, is unable to properly staff its own stores at times.

With the backing of the $100B+ revenue Kroger, both businesses will benefit from superior pricing, scale, and resources. Cerberus must be sweating its purchase of Jewel in 2013. I think Roundy’s will increase share and profitability in both of its markets.

Deal not a reason to buy either stock

Unfortunately, I do not think the Roundy’s deal is a reason to buy either stock. The deal spread for Roundy’s shareholders is just a few pennies, and I believe there is little opportunity with a bidder to present a superior offer in the go-shop period.

I think the market appropriately values Kroger at roughly 19x next year’s earnings. However, existing Kroger shareholders should view this acquisition as a great win, and the clear reason why Kroger continues to be the best pure-play grocery operator in the US.

Share Price Strong For Dr. Pepper in October

Why Dr Pepper Snapple Group Inc. Shares Rallied 13% in October

The diversified soft-drink maker delivered another strong quarter for investors. Here’s what you need to know:

What: Shares of beverage giant Dr Pepper Snapple Group (NYSE:DPS) were getting a caffeine buzz last month, rising 13% according to data from S&P Capital IQ. As the chart below shows, shares rose steadily throughout the month as the stock got a jolt from its third-quarter earnings report.

DPS Chart

So what: Riding a growth wave in still beverages, Dr Pepper Snapple shares jumped 6% on Oct. 22, following its earnings release as the soda maker topped expectations on the top and bottom lines. Earnings per share improved from $0.96 a year ago to $1.05, beating estimates by $0.02, while revenues improved 3% to $1.63 billion, above the analyst mark at $1.6 billion. Bottled waters and its Clamato tomato beverage were particularly strong, growing 16% and 15%, respectively. The company also lifted its full-year EPS guidance to $3.92-$3.98, up from a previous range of $3.85-$3.93.

With shares doubling over the last two years, Dr Pepper Snapple has significantly outperformed rivals The Coca Cola Co. (NYSE:KO) and PepsiCo (NYSE:PEP), which have struggled with the domestic decline in soda consumption. Since Dr Pepper Snapple primarily sells its products and North America, the company has escaped many of the currency-related challenges that have plagued its larger peers, and its strong position in still beverages has also been an advantage as more Americans turn away from sugary and diet sodas.

Now what: Much of Dr Pepper Snapple’s gains over the last two years have come because of multiple expansion or an increase in its valuation as its P/E has jumped from 15 to 23.5. That figure is lower than Coke’s or Pepsi’s, but it indicates that the torrid growth investors have seen over the last two years is likely to slow down. Still, the company’s consistent share repurchases and a solid dividend yield of 2.5% should provide reliable and steady growth.

Challenges remain for the soft-drink industry as a whole, but with its diversified portfolio and geographic focus, Dr Pepper Snapple seems to be a better bet than industry leaders Coca-Cola and Pepsi.

7 Stats About Solar Energy That Will Blow You Away

7 Stats About Solar Energy That Will Blow You Away

Do you know which state has the cheapest solar energy?

Image Source: First Solar, Inc.

Solar energy is here to stay, but the solar energy industry remains as complicated as ever. Investors need to know their basic solar stats to tell the stocks that could soar from those that could stumble.
Here are seven stats about solar energy that will blow you away.

1. North Carolina is constructing more utility-scale solar than California

It’s true. While California was the undeniable first mover and front runner on solar power, its solar energy growth has hit a plateau as other states have soared. According to SNL Energy, North Carolina has almost 4,000 MW of utility-scale solar power under development, compared to 3,700 MW in California. While the Tarheel state is sunny, it’s regulation that has really revved things up — by 2021, utilities will be required to pull 12.5% of their power from renewable sources. Duke Energy Corporation (NYSE:DUK), North Carolina’s largest utility, has 13 solar farms in the state, and is about to build its biggest yet (40 MW) with the help of California-based manufacturer First Solar (NASDAQ:FSLR).

2. Solar subsidies are set to subside

The federal Investment Tax Credit (ITC) has been a major boon to solar growth, allowing commercial installers to write off 30% of their total investment costs. The credit is currently set to expire at the end of 2016, however, and no one’s sure whether Congress will renew it. The impending deadline is causing a surge in solar installations, which many analysts believe will be followed by a major dropoff in the years that follow. In First Solar’s latest annual report, the company stated that:

Reduced growth in or the reduction, elimination, or expiration of … economic incentives … could reduce demand and/or price levels for our solar modules, and limit our growth or lead to a reduction in our net sales, and adversely impact our operating results.

3. New energy = solar

Obama Solar

In the first half of 2015, 40% of all new electricity generating capacity came from solar. For 2015, overall, the Solar Energy Industries Association expects photovoltaic (PV) installations to hit 7,700 MW, around 25% above 2014 installation numbers. Those are huge numbers, considering that solar energy still accounts for just 0.4% of our nation’s total electricity generation.

4. Prices are plummeting

In the energy economy, bottom lines matter more than any environmental aspirations. Solar technology has made significant strides in the past few years, becoming increasingly price competitive with other fuels. According to the Solar Energy Industries Association, average installed PV system prices fell 6% from 2013 to 2014, and have dropped around 53% from 2010 to 2014. Utility-scale systems, in particular, have enjoyed great success reaching cost parity. First Solar claims that its own modules are on par with coal, nuclear, and natural gas combined cycle plants in the United States.

5. Rooftop solar is the fastest growth there is

Utility-scale solar projects are grabbing a lot of attention with their cheap costs and supersized projects. First Solar alone has installed more than 10,000 MW worth of major projects worldwide. But 2014 marked a record year for residential solar as well. In 2014, residential installations broke the 1,000 MW mark, hitting 1,200 MW of rooftop solar systems. It’s enjoyed greater than 50% annual growth for the past three years, and is ramping up faster than either utility-scale or commercial solar energy.

6. California’s solar count is ridiculous

According to the latest estimates, there are 291,513 solar panel systems in California. That’s about one system for every 130 people. In second place, Arizona’s count clocks in at 49,498, equivalent to a measly 17% of California’s. And with less than 10 total counted panels, Oklahoma, Puerto Rico, and North Dakota bring up our nation’s renewable energy rear.

7. Solar is cheapest in Maine

While California is leading the way in capacity, it’s 32nd when it comes to average cost per watt. At $4.16 per watt, Maine is home to the cheapest solar installations in the states. But with only 700 modules generating 7 MW of capacity, that price point hasn’t convinced many Mainers. For states with more than 100 MW installed, Texas is the most affordable at $5.38 per watt. And for the priciest panels around, head to South Carolina, where residents currently pay an average of $9.27 per watt.

Rocky Mountain High Brands, Inc. (RMHB) Trademark Granted for New CBD Line-Up of Products

Rocky Mountain High Brands, Inc. (RMHB) Trademark Granted for New CBD Line-Up of Products

DALLAS, Nov. 10, 2015 (GLOBE NEWSWIRE) —
Rocky Mountain High Brands, Inc. (RMHB) announced today that they have received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on their new Blue Leaf design. Upon completion of the process showing that the mark is in service, a trademark will be issued.
When the United States Patent and Trademark Office (USPTO) intends to issue a trademark, it sends the applicant a Notice of Allowance. For this to happen, an applicant provides information such as product description, design, and blueprints or drawings. A patent examiner then processes the patent application, and ultimately decides whether a patent should be issued. For the patent to be issued, the applicant must complete two additional steps after receiving the notice — pay the required issue fee and submit any final drawings. In the United States, a Trademark is a form of legal protection granted to the assignee.
Currently, Rocky Mountain High Brands is marketing and selling a line-up of beverages in the marketplace that contain 100 mg of hempseed extract in each 12 oz. can. Seeds of the plant cannabis sativa – also known as hemp seed, contain all the essential amino acids and essential fatty acids necessary to maintain healthy human life. No other single plant source has the essential acids in such an easily digestible form, nor has the essential fatty acids in as perfect a ratio to meet the nutritional needs of human beings. Thus, hemp seed and hemp seed oil may be considered to be the most nutritionally complete food source in the world.
In the very near future, Rocky Mountain High Brands will launch a line-up of their Blue Leaf beverages that will include 25mg of cannabidiol (CBD) per container.
To learn more about the numerous consumer benefits of CBD, please click on the following link:
See the new Rocky Mountain High Hemp Beverage can:
One of the most famous shapes in the world is the iconic contour fluted lines of the Coca-Cola bottle. In 1906, The Coca-Cola Company introduced a diamond shaped label with a colorful trademark to stand out from the infringers. On November 16th, 1915 incorporated into the lettering on the final design of the bottle. It is interesting to note that the patent submission was made without the signature embossed Coca-Cola script lettering. This was done to protect the secrecy of the design and the ultimate client.
“Consumers purchasing decisions are influenced by trademarks and designs and the reputation that such brands represent. We believe the new Rocky Mountain High’s Blue Leaf conveys a positive, intellectual and emotional message in people’s minds. Trademarks and design patents provide value beyond our core business and will help pave the way for expansion of a worldwide market and increase the valuation of the Company,” said Jerry Grisaffi, Founder of Rocky Mountain High Brands.
For Rocky Mountain High Distribution Contact:
Todd Kornely: (972) 804-9620
For Rocky Mountain High CBD Opportunities:
Jason Robillard: (303) 665-5828
About Rocky Mountain High Brands, Inc.:
Our Mission is to be the premier Hemp-Infused Beverage Company in the World. RMHB formerly traded as THCZ.
Visit our Corporate Website at:
Investors Hangout is the only authorized Investors blog page for Rocky Mountain High Brands, Inc.

Green Cures Announces and the Addition of New Products

Green Cures Announces and the Addition of New Products

WHITTIER, CA / ACCESSWIRE / November 9, 2015 /

Green Cures & Botanical Distribution Inc. (PINKSHEETS: GRCU) (“Green Cures”), a cannabis and industrial hemp products innovator announced today that the newly redesigned website is fully operational and is currently processing orders from customers across the United States. Additionally, Green Cures is excited to announce the addition of new products and the availability of CBD Capsules, Vaporizers, and CBD Ointments through its e-commerce platform.

Green Cures Hemp Extract-CBD Capsules contain 25 milligrams of CBD from agricultural hemp per serving; capsules are Non-GMO, Gluten Free, and 100% Vegetarian. The company is also excited to announce the immediate availability of its new AllCBD Vape Pen with cartomizer; which comes with .5ML of hemp oil containing 7% CBD extract. AllCBD Vape Pens includes a black battery with stylus and charger. GRCU, through is now shipping CBD Ointment, which is available in natural, lavender and lemon scents. In addition to the ointment, GRCU is also shipping one fluid ounce of Green Cures Hemp Extract. The Hemp Extract contains your choice of either 200 mg or 500 mg of CBD-rich oil, and are currently being offered in three different flavors: natural, vanilla and peppermint.

GRCU is also very excited about the many new developments taking place with Jimi Hendrix Icon Beverages. The company will start to share the impressive details within the next week.

Joe Tragesser, Green Cures CEO stated, “GRCU has been working tirelessly to get up and running and we have been impressed with the current orders the company is receiving, and fully expect all stakeholders and customers will enjoy the addition of the new products to the Green Cures line up.” Mr. Tragesser further stated, “We are very excited about all the great things that are taking place with Jimi Hendrix Icon Beverages, and are equally excited to start sharing all the details. As promised, we will continue to bring top quality products to the market. As we continue to progress, we will keep all our shareholders informed with updates as they become available”

It is important to note that does not carry any type of products that are considered controlled substances at the federal level. All products being marketed and sold by the company comply with federal guidelines. Therefore, Green Cures is able to market, distribute and sell its hemp extract products online and through retailers across the nation.

About Green Cures & Botanical Distribution Inc.:  
Green Cures & Botanical Distribution Inc. is a development stage company that retails and wholesales hemp-infused nutritional, botanical, sports, and body care products. The company is currently Web-based and focuses on online retailing. Green Cures & Botanical Distribution Inc. operates a diverse portfolio of products and services within the botanical and cannabis industry, as permitted by law. From concept to production and distribution, Green Cures & Botanical Distribution Inc. is continuously creating and introducing products that promote a healthy life style.

About InStep Holdings LLC:

We are a company of people engaged in the production of food and beverages committed to creating value to benefit all our stakeholders. InStep will be recognized as an innovative business incubator and holding company as our aim is to invest in and build a great company. Our network of relationships and our ability to leverage those relationships will be unparalleled. Each aspect of creating, developing, distributing, marketing, and selling a product is connected and collaborative.
FDA Statement: The statements contained in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.